2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

5783 Final minimal residual disease (MRD) dynamics analysis in patients with newly diagnosed multiple myeloma (NDMM) receiving subcutaneous daratumumab plus lenalidomide versus lenalidomide alone as post-transplant maintenance therapy in the auriga study

Alfred Chung, MD, Larry D Anderson Jr, MD, PhD2, Laahn Foster, MD3, Chakra P Chaulagain, MD4, Erin M. Pettijohn5, Andrew J. Cowan, MD6, Caitlin Costello, MD7, Sarah M. Larson, MD8, Doug W. Sborov, MD, MS9, Kenneth H. Shain, MD, PhD10, Rebecca Silbermann, MD11, Peter Voorhees, MD12, Mitul Gandhi, MD13, Maria Krevvata14, Mai Ngo15, Sharmila Patel, PhD16, Jennifer Phillips17, Vipin Khare, MD18, Thomas S. Lin, MD, PhD19, Ashraf Badros, MD20
1 Department of Medicine, University of California San Francisco, San Francisco, California, United States
2 Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
3 Division of Hematology Oncology, University of Virginia, Charlottesville, Virginia, United States
4 Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida, Weston, Florida, United States
5 Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States
6 Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States
7 Moores Cancer Center, University of California San Diego, La Jolla, California, United States
8 Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
9 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
10 Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida, United States
11 Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, United States
12 Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, North Carolina, United States
13 Virginia Cancer Specialists, Warrenton, Virginia, United States
14 Johnson & Johnson, Spring House, Pennsylvania, United States
15 Cytel, Cambridge, Massachusetts, United States
16 Johnson & Johnson, Horsham, Pennsylvania, United States
17 Johnson & Johnson, Horsham, Pennsylvania, United States
18 Johnson & Johnson, Horsham, Pennsylvania, United States
19 Johnson & Johnson, Horsham, Pennsylvania, United States
20 Greenbaum Cancer Center; University of Maryland, Baltimore, Maryland, United States

Introduction: Patients (pts) who are MRD positive (+) after autologous stem cell transplant (ASCT) remain at increased risk for disease recurrence, highlighting the need for maintenance therapy. Lenalidomide (R) maintenance is a current standard of care following ASCT for pts with NDMM. Prior analyses of the phase 3 AURIGA study (NCT03901963) showed that the addition of subcutaneous daratumumab (DARA SC) to R (D-R) maintenance improved MRD-negative (−) conversion rates and progression-free survival (PFS) vs R alone in pts without anti-CD38 induction/consolidation who were MRD+ after ASCT. Here we report results on the evolution of MRD status during maintenance with D-R vs R and its impact on long-term outcomes from the final analysis of AURIGA.

Methods: AURIGA enrolled pts with NDMM aged 18-79 yrs without prior anti-CD38 therapy who were in very good partial response or better and MRD+ (10–5; next-generation sequencing [NGS]; Adaptive Biotechnologies) after ≥4 induction cycles and ASCT and enrolled within 6 mos of ASCT. Pts were randomized 1:1 to receive D-R or R maintenance for 36 (28-day) cycles or until disease progression, unacceptable toxicity, or consent withdrawal. MRD was assessed by NGS at 12, 18, 24, and 36 mos after maintenance start. MRD data at the 10–6 threshold are reported herein. PFS was assessed by computerized algorithm. MRD, sustained MRD, and PFS are reported in all randomized pts.

Results: 200 pts were randomized (D-R: n=99; R: n=101), with pt characteristics generally well balanced between groups. At baseline, the median age was 62 (range 35-78) yrs; 59.5% of pts were male; 22.0% were Black; and 39.0% were MRD− (10–4 threshold). At diagnosis, 24.3% had ISS stage III disease, 20.4% had high cytogenetic risk (del[17p], t[4;14], or t[14;16]), and 34.1% had revised high cytogenetic risk (also including t[14;20] or gain/amp[1q]).

At a median follow-up of 58.2 mos, overall MRD− (10−6) conversion rates were higher with  D-R vs R (37.4% vs 13.9%; OR 3.76 [95% CI 1.87-7.56]; P=0.0002); a benefit was seen with D-R vs R irrespective of cytogenetic risk status at diagnosis (standard risk: OR 3.68; high risk: OR 2.44; revised standard risk: OR 3.24; revised high risk: OR 3.90). Accumulative MRD− conversion rates were also higher with D-R vs R: by 12 mos (23.2% vs 5.0%; OR 5.97 [95% CI 2.15-16.58]; P=0.0002), 18 mos (30.3% vs 8.9%; OR 4.44 [95% CI 1.98-9.96]; P=0.0001), 24 mos (35.4% vs 10.9%; OR 4.51 [95% CI 2.13-9.56]; P<0.0001), and 36 mos (37.4% vs 13.9%; OR 3.76 [95% CI 1.87-7.56]; P=0.0002). Sustained MRD− rates were higher with D-R vs R for ≥12 mos (22.2% vs 2.0%; OR 14.26 [95% CI 3.24-62.80]; P<0.0001) and ≥24 mos (14.1% vs 2.0%; OR 8.29 [95% CI 1.82-37.78]; P=0.0015). Among pts who achieved MRD− (10–6), the MRD+ recurrence occurred less frequently with D-R vs R (6/37 [16.2%] vs 6/14 [42.9%] pts) and median time to MRD+ recurrence was longer with D-R (11.2 vs 6.1 mos); 3/6 D-R pts and 1/6 R pts with MRD+ recurrence had a PFS event.

PFS favored D-R vs R irrespective of baseline MRD status (MRD− [10–4]: HR 0.50 [95% CI 0.21-1.22], P=0.1231; MRD+ [10–4]: HR 0.64 [95% CI 0.36-1.14], P=0.1301). Across treatment groups, pts who achieved MRD− (10–6) conversion had improved PFS compared with pts who remained MRD+ (median not reached vs 54.0 mos; HR 0.17 [95% CI 0.07-0.39]; P<0.0001). PFS numerically favored D-R vs R for both pts who achieved MRD− (10–6) conversion (median not reached for D-R or R; HR 0.68 [95% CI 0.12-3.73]; P=0.6548) and pts who remained MRD+ (median 57.7 vs 47.4 mos; HR 0.82 [95% CI 0.50-1.36]; P=0.4448).

Conclusions: With longer follow-up, D-R maintenance was associated with higher MRD− conversion and sustained MRD− rates and a lower MRD+ recurrence rate than R alone in pts who were anti-CD38 naive and MRD+ after ASCT. D-R nearly tripled the rate of MRD− (10–6) conversion vs R, reinforcing the ability of DARA SC to drive deep remissions, which translate into superior long-term PFS. Sustained MRD− rates lasting ≥12 and ≥24 mos were 10-fold and 6-fold higher, respectively, with D-R vs R. Pts who achieved MRD− conversion in the D-R group were less than half as likely to develop MRD+ recurrence vs the R group. Achieving MRD− was associated with improved PFS, highlighting the clinical importance of the higher MRD− rates achieved with DARA SC. Overall, these results further support the role of D-R maintenance in attaining and sustaining deep MRD− responses after ASCT in pts with NDMM.

Alfred Chung, MD: AbbVie, Astra-Zeneca, BMS, Caelum, CARsgen, Cellectis, J&J, K36 Therapeutics, and Merck - Research Funding; Johnson & Johnson and Bristol Myers Squibb - Consultancy (Includes expert testimony)